Korean Circ J.  2003 Sep;33(9):754-761. 10.4070/kcj.2003.33.9.754.

The Effects of Abciximab on Left Ventricular Remodeling in Patient with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

• Won KH
• Lee SH
• Gwon HC
• Kim HJ
• Im ES
• Lee HH

• KMID: 2145620
• DOI: http://doi.org/10.4070/kcj.2003.33.9.754

Abstract

BACKGROUND AND OBJECTIVE
Abciximab has been shown to have beneficial effects beyond the improvement in the patency of an infarct-related artery and the microvascular integrity. However, it remains uncertain whether abciximab may lead to beneficial effects on the left ventricular remodeling in patients with an acute myocardial infarction, treated with primary percutaneous coronary intervention (PCI). Therefore, whether abciximab is effective in the left ventricular remodeling in patients with acute myocardial infarction, treated with primary PCI, was investigated.
SUBJECTS AND METHODS
The study included 28 patients with an acute myocardial infarction (1 vessel disease) that had received either a primary PCI alone (group A, n=14) or an abciximab+primary PCI (group B, n=14). The baseline characteristics of the two groups were similar, with the exception of a thrombusburden lesion. All patients were examined by echocardiography within 72 hours, and at an average 11.7 months after the acute myocardial infarction. The change in the left ventricular end-diastolic volume index, end-systolic volume index and ejection fraction, between the two groups, were compared.
RESULTS
At an average follow-up of 11.7 months, the left ventricular volume indices were smaller, and the left ventricular ejection fraction higher, compared with those at the baseline in each group. The change of the left ventricular end-diastolic volume index (-7+/-3 mL/m2 vs. -9+/-2 mL/m2, p=0.56), the left ventricular end-systolic volume index (-8+/-3 mL/m2 vs. -9+/-2 mL/m2, p=0.73) and the left ventricular ejection fraction (7+/-3% vs. 9+/-2%, p=0.49) did not show significant differences between groups A and B.
CONCLUSION
These results suggest that abciximab does not improve the left ventricular remodeling in patient with an acute myocardial infarction, treated with primary PCI.

Keyword

Platelet aggregation inhibitors; Myocardial infarction; Remodeling

MeSH Terms

Arteries
Echocardiography
Follow-Up Studies
Humans
Myocardial Infarction*
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors
Stroke Volume
Ventricular Remodeling*
Platelet Aggregation Inhibitors